pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,045 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
    Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
    STAT · 2mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
    In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
    STAT · 2mo ago↗ source
← prev
page 31 of 42
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Hims’ sales miss as telehealth competition grows
    Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • <![CDATA[Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk]]>
    <![CDATA[A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma]]>
    <![CDATA[Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]>
    <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]>
    <![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>
    onclive · 2mo ago↗ source
  • STAT+: STAT examines America’s deadliest drug
    STAT examines America's failure to address excessive alcohol use across decades.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
    The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
    STAT · 2mo ago↗ source
  • <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]>
    <![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Unmet Needs in Endometrial Cancer]]>
    <![CDATA[Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs]]>
    <![CDATA[In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper exp…
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
    <![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]>
    <![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing ADCs in Endometrial Cancer]]>
    <![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]>
    <![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>
    onclive · 2mo ago↗ source
  • STAT+: Capsida says it still doesn’t know what caused gene therapy death
    Some in the gene therapy field lament lost time while Capsida kept silent about the brain receptor it was targeting when things went wrong.
    STAT · 2mo ago↗ source
  • STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
    As new AI models for predicting sepsis hit the market, experts say performance alone will not drive adoption by hospitals.
    STAT · 2mo ago↗ source
  • PCOS’s new name is PMOS, a small letter change that required a big scientific process
    A revised name for PCOS — polyendocrine metabolic ovarian syndrome, or PMOS — was introduced in a paper published Tuesday.
    STAT · 2mo ago↗ source
  • STAT+: Despite its toll, alcohol is still an awkward subject in the doctor’s office
    Alcohol screening and counseling are too often compressed or skipped during doctor's visits — a gap that is costing patients and the health care system.
    STAT · 2mo ago↗ source
  • STAT+: Alcohol is wreaking havoc on U.S. public health. American society looks the other way
    The Deadliest Drug, a new investigative series, shows that the alcohol epidemic is a generational failure of the medical and public health systems, of industry, and of government.
    STAT · 2mo ago↗ source
  • 6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
    Alcohol is the culprit behind the United States' most enduring and overlooked drug crisis. Here are 6 takeaways from STAT's new investigative series, The Deadliest Drug.
    STAT · 2mo ago↗ source